Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Enspryng
Satralizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor and is used to treat neuromyelitis optica spectrum disorder (NMOSD). IL-6 plays a significant role in the inflammatory process that drives NMOSD. By blocking the IL-6 receptor, satralizumab inhibits IL-6 signaling, thereby reducing inflammation and preventing relapses.
Satralizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody positive.
Outcome:
Increased risk of infection
Mechanism:
Suppressed immune response
Outcome:
Increased risk of gastrointestinal bleeding
Mechanism:
Additive effect on platelet function
Outcome:
Generally safe
Mechanism:
No known significant interaction
Most likely new formulation: Subcutaneous injection for improved patient convenience and compliance. (Year: 2025, 70% confidence)
Based on clinical trial data and post-market surveillance, satralizumab is expected to maintain its current regulatory status with continued monitoring for long-term safety and efficacy.
Immunosuppressant, Monoclonal Antibody
Recombinant humanized monoclonal antibody